Abstract
Exacerbation of symptoms of obsessive-compulsive disorder (OCD) during COVID-19 or new onset of the OCD symptoms resulting from COVID-19 infection is an understudied area of research. It is possible that increased proinflammatory immune status is associated with the onset of obsessive-compulsive symptoms in patients with COVID-19 and that targeted anti-inflammatory treatments for COVID-19 infection can mitigate the new onset of Obsessive-Compulsive (OC) spectrum symptoms. In this review, we cover OCD pathogenesis as related to COVID-19, summarize the impact of cytokines on behavior, and suggest that anti-cytokine treatments can help mitigate post-COVID-19 and new onset of the OC symptoms.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 367-373 |
| Number of pages | 7 |
| Journal | Journal of Psychiatric Research |
| Volume | 149 |
| DOIs | |
| State | Published - May 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- COVID-19
- Neuroinflammation
- OCD
- Obsessive-compulsive disorder
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry
Fingerprint
Dive into the research topics of 'Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS